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ABSTRACT
Clinical history, questionnaire data and response
to antisecretory therapy are insufficient to make a
conclusive diagnosis of GERD in isolation, but are of
value in determining need for further investigation.
Conclusive evidence for reflux on oesophageal testing
include advanced grade erosive oesophagitis (LA grades
C and D), long-segment Barrett’s mucosa or peptic
strictures on endoscopy or distal oesophageal acid
exposure time (AET) >6% on ambulatory pH or pHimpedance monitoring. A normal endoscopy does not
exclude GERD, but provides supportive evidence refuting
GERD in conjunction with distal AET <4% and <40 reflux
episodes on pH-impedance monitoring off proton pump
inhibitors. Reflux-symptom association on ambulatory
reflux monitoring provides supportive evidence for
reflux triggered symptoms, and may predict a better
treatment outcome when present. When endoscopy
and pH or pH-impedance monitoring are inconclusive,
adjunctive evidence from biopsy findings (histopathology
scores, dilated intercellular spaces), motor evaluation
(hypotensive lower oesophageal sphincter, hiatus hernia
and oesophageal body hypomotility on high-resolution
manometry) and novel impedance metrics (baseline
impedance, postreflux swallow-induced peristaltic
wave index) can add confidence for a GERD diagnosis;
however, diagnosis cannot be based on these findings
alone. An assessment of anatomy, motor function,
reflux burden and symptomatic phenotype will therefore
help direct management. Future GERD management
strategies should focus on defining individual patient
phenotypes based on the level of refluxate exposure,
mechanism of reflux, efficacy of clearance, underlying
anatomy of the oesophagogastric junction and
psychometrics defining symptomatic presentations.

Introduction

To cite: Gyawali CP,
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GERD has an estimated worldwide prevalence
of 8%–33%, involves all age groups and both
genders1 and carries a price tag estimated at >US$9–
US$10 billion/year in the USA alone, largely related
to proton pump inhibitors (PPI) use and diagnostic
testing.2 The current paradigm of GERD diagnosis hinges on the identification of oesophageal
mucosal lesions or troublesome symptoms caused by
gastro-oesophageal reflux.3 A putative GERD diagnosis is bolstered by a favourable response to PPI
therapy.4 The primary determinant of mucosal injury
is excessive oesophageal acid exposure attributable to
anatomical or physiological defects of the oesophagogastric junction (EGJ) and oesophageal peristalsis.5

GERD symptoms, however, have multiple potential determinants including the number of reflux
episodes, the proximal extent to which the refluxate
migrates, the acidity of the refluxate, oesophageal hypersensitivity and cognitive hypervigilance.
Consequently, depending on the clinical context, the
defining features of GERD can be pathology, physiology or symptomatology. In this paradigm, oesophageal testing is often undertaken to define optimal
management, be that PPI therapy, antireflux surgery
(ARS) or cognitive behavioural therapy.
The aim of the GERD consensus process was
to determine modern indications for oesophageal
testing in GERD, and as an extension to that aim,
to define criteria for a clinical diagnosis of GERD.
The consensus process started in 2014, when the
primary aims were formulated, followed by a
literature search and grading of evidence. There
was extensive discourse within a multinational
group of GERD experts over 2 years, following
which consensus statements were developed and
published.6–8 These consensus statements were
adapted for the practising gastroenterologist by a
cohort of international experts at the Lyon GERD
consensus meeting in November 2017, the conclusions from which are presented in this manuscript.

Diagnosis of GERD

GERD is empirically diagnosed and treated in
clinical practice based on the clinician’s symptom
assessment. Indications for testing include treatment failure, diagnostic uncertainty and treating
(or preventing) complications of GERD. However,
diagnostic testing may or may not support the initial
diagnosis, as the criteria defining GERD are specific
to each testing modality. Consequently, understanding the performance characteristics of each
diagnostic modality and recognising evidence that
supports or refutes the clinical impression of GERD
is crucial. The Lyon Consensus evaluated GERD
diagnostic tests from that perspective, and test
results were categorised as being adequate to establish or refute a GERD diagnosis or inconclusive in
the absence of additional supportive evidence.
The primary focus of oesophageal testing has
hitherto been restricted to detection of excessive
acid reflux as indicative of pathological GERD,
supported by reflux-symptom association analysis.
The threshold value discriminating abnormal from
normal oesophageal acid exposure with 24 hour
pH-metry was initially selected based on evidence
that higher acid exposure is associated with the presence of reflux oesophagitis.9 However, the focus of
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Recent advances in clinical practice

Clinical history and questionnaires

Typical GERD symptoms (heartburn and acid regurgitation) are
more likely than atypical symptoms to respond to treatment,
emphasising the value of an accurate clinical history.5 However,
when compared with objective evidence of GERD defined by
pH-metry or endoscopy, even an expert history by a gastroenterologist has only 70% sensitivity and 67% specificity,12
reiterating the distinction between a physiology-based and a
symptom-based GERD diagnosis. Likewise, questionnaires such
as the reflux disease questionnaire (RDQ) and gastroesophageal
reflux disease questionnaire (GERDQ) have similar limitations
when compared with physiological testing.12–14 However, in
clinical practice, diagnosing and treating GERD based on typical
symptoms is pragmatic and endorsed by societal guidelines,4
even though these symptoms are neither sensitive nor specific
for objectively defined GERD.12

Proton pump inhibitor trial

Although pragmatic, symptomatic response to PPI therapy does
not equate to a GERD diagnosis, exhibiting an imperfect correspondence with objectively defined disease. On average, 69%
of patients with oesophagitis, 49% of patients with non-erosive
reflux disease (NERD) and 35% of patients with normal endoscopy and pH-metry gain symptom relief from a PPI trial.15 Hence,
when evaluated as a diagnostic test for GERD among patients with
heartburn, an empiric PPI trial has a sensitivity of 71% and specificity of only 44% compared with the combination of endoscopy
and pH-metry.12 16 With atypical symptoms (chest pain, chronic
cough, laryngitis, etc), PPI response rates are much lower than
with heartburn, thereby diminishing the utility of that approach to
diagnosis.17 A major limitation of the ‘PPI test’ is the strong modulation of symptoms by oesophageal hypersensitivity18 19; there is
also variation in PPI dosing and duration of the test.20 Nonetheless,
despite low specificity and high placebo response,21 the empiric
PPI treatment approach is less costly than diagnostic testing22 and
is endorsed by societal guidelines4 undoubtedly leading to the
overdiagnosis of GERD and overuse of PPIs.

Endoscopy and biopsy

When putative GERD symptoms do not respond to empiric PPI
therapy, upper endoscopy (EGD) is advised both to evaluate for
GERD complications and to detect potential alternative diagnoses that might redirect therapy. High-grade oesophagitis (LA
grades C or D), Barrett’s oesophagus or peptic stricturing are
considered confirmatory evidence for GERD.6 However, erosive
oesophagitis is found in only 30% of treatment-naïve patients
with heartburn and in <10% when already taking a PPI.23 24
Furthermore, most of that is low-grade, and lower grades of
oesophagitis, particularly LA grade A, are non-specific, found
in 5%–7.5% of asymptomatic controls.25–27 When accurately
defined, LA grade B oesophagitis provides adequate evidence
for initiation of medical management of GERD, but problems
with interobserver variability led an expert panel to conclude
1352

that additional pH-metry evidence is requisite prior to pursuing
ARS.28 Barrett’s oesophagus is observed in 5%–15% of patients
with chronic GERD,29–31 but histological confirmation is documented in only 50% of these. In summary, EGD findings can be
clinically important and specific for GERD, but EGD has a low
sensitivity in GERD diagnosis.
The Rome IV consensus recommended oesophageal biopsies during EGD to rule out eosinophilic oesophagitis.32 Biopsies may also have value in differentiating NERD (with positive
pH-metry) from reflux hypersensitivity, functional heartburn
and controls when scored using a structured histopathological
protocol evaluating papillary elongation, basal cell hyperplasia,
dilated intercellular spaces, intraepithelial inflammatory cells,
necrosis and erosions33 34; changes that resolve following adequate
GERD therapy.35 However, histopathological findings can overlap
between the groups studied, and are not conclusive of GERD.
Identification of dilated intercellular spaces on electron microscopy
suggests mucosal injury from reflux,36 37 but clinical application is
limited. The widespread adoption of histopathological examination for GERD injury is hindered by the cumbersome protocol and
need for a dedicated oesophageal pathologist.33 38 39

Ambulatory reflux monitoring

Ambulatory reflux monitoring can provide confirmatory
evidence of GERD, in patients with normal endoscopy, atypical symptoms and/or when contemplating ARS.6 Reflux monitoring demonstrates the consequence of GERD pathophysiology,
evident as either excessive oesophageal acid exposure time
(AET) or reflux episodes, rather than the mechanism by which
that occurs. Reflux-symptom association uses simple ratios and
statistical tests to determine whether reflux episodes co-occur
with symptoms, and adds value to ambulatory reflux monitoring. Hence, reflux monitoring can confirm or exclude pathological GERD, although not always conclusively.
The primary outcome of a 24-hour pH-metry study is the AET.
Extending recording time to 48 or 96 hours with the wireless pH
monitoring system increases the diagnostic yield40–42 and test reproducibility,43 and is particularly useful when a transnasal catheter
was not tolerated or yielded a negative result despite high suspicion of GERD.40 44 However, wireless pH monitoring is expensive,
limiting its availability. Another variation on reflux monitoring is
pH-impedance monitoring, which characterises reflux events with
both a pH electrode and a series of impedance electrodes. Since
pH-impedance detects all reflux (liquid, gas or mixed) regardless of
acidity, and defines the direction of flow, it is considered the gold
standard.6 45 However, the added yield is limited,46 47 the test is not
widely available and the interpretation is laborious.
Reflux monitoring can be done ‘on’ or ‘off ’ PPI therapy in
patients with persistent and/or atypical symptoms despite PPI
therapy. The Lyon Consensus proposes that testing always be
performed off therapy to demonstrate baseline AET in ‘unproven
GERD’, meaning no (or low-grade) oesophagitis at endoscopy,
and no prior positive pH testing.8 Testing off therapy is also
recommended when done to evaluate for ARS.6 32 In contrast,
the Lyon Consensus proposes that patients with ‘proven GERD’
(prior LA grade C or D oesophagitis, long segment Barrett’s
oesophagus or prior abnormal pH-metry) be evaluated on
double-dose PPI therapy to establish correlation between refractory symptoms and reflux episodes and/or to exclude inadequate acid suppression or poor compliance as the mechanism
of persisting symptoms. This assessment requires pH-impedance
(vs pH) monitoring since most reflux episodes on PPI therapy
are weakly acidic (pH 4–7).48 49
Gyawali CP, et al. Gut 2018;67:1351–1362. doi:10.1136/gutjnl-2017-314722
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current GERD management is on healing mucosal disease and on
managing symptoms. The association of oesophageal acid exposure
with patient symptoms is weak,10 11 making sole reliance of this
metric problematic. Expansion of testing to include oesophageal
mucosal impedance, manometry, histopathology and psychometrics may help in this regard, potentially identifying distinct GERD
phenotypes with unique management implications. Each test adds
a piece to the overall puzzle of symptom generation, disease pathophysiology and precision management.

Recent advances in clinical practice

Interpretation of pH and pH-impedance monitoring

Among the pH monitoring metrics, AET is the most reproducible,58 is reliably extracted from automated analysis and is predictive of response from medical and surgical reflux therapy.59 60
However, the significance of an abnormal AET is proportionate
to the degree of abnormality, and the Lyon Consensus proposes
that AET <4% be considered definitively normal (physiological)
and >6% be considered definitively abnormal6 with intermediate values between these limits being inconclusive. Another
outcome metric of pH-impedance monitoring is the number of
reflux episodes (acidic, weakly acidic or weakly alkaline) with
the caveat that this is overestimated by the automated analysis
and requires manual review of the tracing.61 The Lyon GERD
Consensus proposes that >80 reflux episodes per 24 hours are
definitively abnormal, while a number <40 is physiological6
and intermediate values inconclusive. The clinical relevance of
an abnormal number of reflux episodes remains incompletely
defined, although recent preliminary data demonstrate improvement of regurgitation verified by increased reflux episodes
following magnetic sphincter augmentation.62 Consequently,
this is considered an adjunctive measure to be used when AET
is inconclusive (ie, between 4% and 6%). pH-Impedance monitoring assists diagnosis of belching disorders and rumination,
which can mimic reflux disease. Additional impedance parameters such as bolus exposure, baseline impedance and postreflux
swallow-induced peristaltic wave (PSPW) also have potential as
reflux metrics, but outcome data are currently limited.

Reflux-symptom association

Both pH monitoring and combined pH-impedance monitoring
provide analysis of the temporal association between symptoms
with a crisp onset (eg, heartburn, regurgitation, chest pain, cough
or belching) and reflux episodes.63 The time window applied for
reflux-symptom association analysis is 2 min.64 65 The Symptom
Index (SI) is the percentage of symptom events preceded by reflux
episodes,66 and the optimal SI threshold for heartburn is 50%.67
The disadvantage of the SI is that the number of reflux episodes
is not considered leaving open the possibility of chance association. The Symptom Association Probability (SAP) and the Ghillebert Probability Estimate (GPE), also known as Binomial Symptom
Index (BSI), use more complex statistical calculations to express
the probability that symptom events and reflux episodes are associated68 69 and are considered positive if the probability (P value)
of the observed association occurring by chance is <5%. Both SAP
and GPE/BSI take all relevant components, that is, total numbers
of symptom events, reflux episodes and reflux-related symptom
events, into account. In summary, SI is a measure of ‘effect size’,
whereas SAP is a measure of probability. As such the two metrics
are complementary, measure different things and cannot be
compared with each other. The combination of a positive SI and
positive SAP provides the best evidence of a clinically relevant association between reflux episodes and symptoms.6 70 71 Both the SI
and SAP are predictive of the effect of medical and surgical antireflux therapy, independent of AET.72–75
Gyawali CP, et al. Gut 2018;67:1351–1362. doi:10.1136/gutjnl-2017-314722

The reliability of reflux-symptom association analysis is critically dependent on proper execution of the reflux monitoring
procedure and meticulous analysis protocols including careful
selection of symptoms of interest. Patients must be instructed
to use the symptom event button on the portable data logger
accurately and to fill in the symptom diary accurately. The
outcome of symptom association analysis is more reliable when
at least three symptom events occur during the test.6 When
cough is the symptom of interest, an automated acoustic or
manometric cough monitor is necessary to accurately capture
cough events.76 77 Prolonged wireless pH monitoring increases
the yield of symptom association analysis,40 41 as does combined
pH-impedance monitoring with the detection of weakly acidic
reflux episodes.78 This requires manual analysis, as automated
analysis significantly overdetects weakly acidic reflux episodes
and inaccurately reports association with non-acid reflux events
in nearly 20% of cases.61 However, ‘rapid’ visual analysis limited
to the 2 min window preceding each symptom event yields
SI and SAP values concordant with a full visual analysis, with
excellent intraobserver and interobserver agreement.79 Although
pH-impedance monitoring provides analysis of symptom-reflux
association on PPI therapy, testing off PPI therapy increases the
number of symptoms reported, which increases the chance of a
positive symptom-reflux association.80
Reflux-symptom association analysis has a high degree of
reproducibility, the SI being somewhat less reproducible than
the SAP.81 Monte Carlo simulations have identified limitations of
reflux-symptom association analysis, especially when acid exposure is low and symptom events are few.82 83 If new methods
for reflux-symptom association are developed in the future,
rigorous outcome testing will be needed to define superiority to
the existing metrics.

Novel metrics

Two novel impedance-detected parameters, the PSPW index and
baseline impedance have been investigated within GERD phenotypes.84 85 These metrics may augment the diagnostic value of
impedance-pH testing, especially in discriminating patients with
GERD from those with functional heartburn.86–88 In health, reflux
episodes trigger primary peristalsis to neutralise acidified oesophageal mucosa with saliva. This is evident as the antegrade progression of impedance decline within 30 s of a reflux episode (PSPW)
on a pH-impedance study.87 The PSPW index, which currently
requires cumbersome manual calculation as it is not programmed
into the analysis software, consists of the proportion of reflux
episodes on pH-impedance monitoring followed by a PSPW. The
PSPW index reflects the integrity of primary peristalsis stimulated
by reflux episodes, correlates with contraction reserve assessed
using multiple rapid swallows (MRS)89 and has excellent performance characteristics in differentiating erosive oesophagitis and
pathological acid exposure from functional heartburn and controls
(sensitivity 99%–100%, specificity 92%).87 90
Baseline impedance values reflect the permeability of the
oesophageal mucosa, both in animal models and healthy volunteers, with lower values found in erosive and non-erosive
GERD.91 92 Low baseline oesophageal mucosal impedance has
been linked to alteration in intercellular space and tight junctions93 94 and to reflux symptoms.95 Since frequent swallows and
reflux events impact measurement, baseline impedance is best
measured from pH-impedance tracings during sleep, termed
mean nocturnal baseline impedance (MNBI) when averaged
from three 10 min periods spaced an hour apart.84 MNBI is
lower in persisting erosive oesophagitis compared with healed
1353
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Assessment of proximal oesophageal or pharyngeal reflux
has also been proposed, but methodology and interpretation
have not been standardised, and outcome studies are currently
lacking.50–53 An additional problem with the pharyngeal pH
probe designed to evaluate both aerosolised and liquid acid
reflux54 is that it detects pharyngeal pH drops in the absence
of concomitant oesophageal pH-impedance events,55 56 even in
patients post-gastrectomy, raising questions about its accuracy.57

Recent advances in clinical practice
Oesophageal high-resolution manometry

A common indication for high-resolution manometry (HRM) is
to accurately place pH or pH-impedance catheters. HRM is also
used to assess peristalsis and to detect alternative major motor
disorders prior to ARS or when symptoms do not improve with
GERD therapy. Consequently, HRM studies are often performed
in the setting of GERD. Nonetheless, although fundamental to
GERD pathophysiology, a pathophysiological classification of
motor findings in GERD was only recently described.7

EGJ barrier function

The most fundamental abnormality in GERD is incompetence of
the EGJ as an antireflux barrier, making quantifying EGJ competence an attractive biomarker. However, the EGJ is a complex
sphincter composed of both the crural diaphragm (CD) and
lower oesophageal sphincter (LES), the relative dominance of
which varies with circumstance. The EGJ pressure varies with
time, respiration and swallowing;, similarly the EGJ morphology
can also vary over time, transitioning between superimposed and
separated CD and LES elements.104 Furthermore, some degree of
EGJ incompetence is physiological, evident by the phenomenon
of transient LES relaxation (TLESR), reflex relaxation of both

Figure 1 Oesophagogastric junction morphology as depicted in HRM. With type 1 morphology the crural diaphragm (CD) component, evident
during inspiration (I), is completely superimposed of the lower oesophageal sphincter (LES) component such that the magnitude of the actual LES
pressure is not discernible. With type 2 morphology, there is partial separation of the LES and CD constituents, but the respiratory inversion point
(RIP) remains at the level of the CD, evident by the decrease observed in the LES pressure band during inspiration. Other characteristics of type 2
morphology are that the LES-CD separation is <3 cm and that the pressure trough between the LES and CD is greater than intragastric pressure. With
type 3 morphology, there is ≥3 cm separation between the LES and CD and the pressure trough between the two is equal to intragastric pressure
during expiration (E). However, the RIP remains at the level of the CD in type 3a and elevated to the level of the LES pressure band with type 3b. This
is evident by the decreases in LES pressure during inspiration in type 3a and increases in LES pressure during inspiration in type 3b.
1354
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oesophagitis,96 in PPI-responsive NERD and chronic cough
compared with PPI-refractory states,84 97 and in erosive oesophagitis, NERD and reflux hypersensitivity compared with functional heartburn and healthy controls.86 87 93 Low MNBI (<2292
ohms) independently predicts response to antireflux therapy,98
links PPI responsive heartburn to reflux better than AET90 and
improves with healing oesophagitis.99 100
Baseline impedance can also be directly measured from the
oesophageal mucosa. Initially, this was done using probes with
impedance sensors that were passed through the endoscope.
Subsequently, the design has improved using two radial sensors
mounted on a 10 cm balloon that is inflated to insure optimal
contact with a long segment of oesophageal mucosa. Baseline
mucosal impedance values correlate with oesophageal mucosal
inflammation, differentiating erosive and non-erosive GERD
from eosinophilic oesophagitis and normal patients with better
specificity (95% vs 64%) and positive predictive value (96% vs
40%) compared with pH monitoring.101–103 Similar to baseline
impedance from pH-impedance monitoring, values normalise
following PPI therapy. Although normative values are not yet
available, ongoing studies should clarify the role of mucosal
impedance measurements in GERD management.

Recent advances in clinical practice

the LES and CD that facilitates gas venting from the stomach.105
Clearly, there are challenges to quantifying EGJ barrier function.
No single HRM metric adequately summarises EGJ competence. Hence, the Lyon Consensus proposes adopting two metrics,
one expressing the anatomical morphology of the EGJ and the
second summarising its contractile vigour. EGJ morphology,
defined by the relationship between the LES and CD, has been
characterised into three subtypes on HRM106 107: type 1 with
superimposed LES and CD, type 2 with axially separated LES and
CD pressure signals separated by <3 cm and type 3 with a ≥3 cm
separation between the LES and CD pressure signatures (figure 1).
Type 3 EGJ morphology is associated with reduced LES pressure
Table 1 Studies that have compared the EGJ-CI among patient and
control populations. Values reported at median (IQR)
Study

Subject groups

EGJ-CI
(mm Hg·cm)

Nicodème et al110

Controls (n=75)
GERD (n=7)
Functional (n=45)

39 (25–55)
18* (8–30)
27 (17–69)

GERD
had +++ abnormal pHimpedance studies
vs partial + or − for
functional

Tolone et al111

Functional (n=39)
GERD (n=91)

22 (10–41)
11* (3–21)

GERD or functional by
endoscopy and pHimpedance testing

Jasper et al112

Controls (n=65)
GERD (n=116)

63 (50–90)
50* (28–70)

GERD by pH-metry

Wang et al113

Controls (n=21)
GERD (n=68)

35 (26–58)
30* (15–53)

GERD patients
underwent
fundoplication

Xie et al114

Controls (n=21)
Oesophagitis (n=39)
NERD (n=38)
Hypersensitive
(n=21)

63 (38–83)
22* (20–31)
26* (15–38)
30* (19–44)

Patients differentiated
by pH-impedance and
symptom correlation

Ham et al108

Controls (n=23)
Oesophagitis (n=25)
NERD (n=16)
Non-GERD ((n=91)

67 (27–79)
28* (4–63)
26* (15-–32)
51 (3–153)

Patients with no GERD
had negative pHimpedance studies

Notes

Methods of EGJ-CI computation were not uniform between these studies, and this
might explain differences in calculated thresholds. NERD: non-erosive reflux disease.
*P<0.05 vs controls or comparator.
EGJ-CI, oesophagogastric junction contractile integral; NERD: non-erosive reflux
disease.
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and lower inspiratory augmentation, which correlates with reflux
severity.106 108 109 However, this relationship is not linear and there
are clear exceptions.
The second HRM metric to quantify EGJ barrier function is
the EGJ contractile integral (EGJ-CI) (figure 2). The EGJ-CI is
calculated using methodology analogous to that for calculating the
distal contractile integral (DCI) with the DCI box set to encompass
the LES and CD over a period of three respiratory cycles above a
threshold of gastric pressure. The calculated ‘DCI’ is then divided
by the duration of the three respiratory cycles to make it independent of time and expressed in units of mm Hg·cm.110 Several
groups of investigators have subsequently tested the performance of
the EGJ-CI in segregating GERD populations (table 1),110–114 with
general agreement that this metric identifies a subset of patients
with severe barrier dysfunction prone to either endoscopic oesophagitis or unequivocally abnormal reflux testing. However, it is also
evident from the spread of normal ranges reported among these
studies that there are likely methodological discrepancies in exactly
how the EGJ-CI is calculated. In view of this, the Lyon Consensus
concluded that the EGJ-CI is a promising metric, but needs further
research before widespread adoption. In an attempt to standardise
methodology among groups, they recommended exclusion of CD
component of the EGJ in instances of type 3 EGJ morphology and
calculation of EGJ-CI above the gastric baseline pressure.
Further insight into the genesis of the EGJ-CI has been gleaned
through studies using three-dimensional (3D)-HRM.115 Isolation
of the CD component of the composite EGJ signal on 3D-HRM
concluded that approximately 85% of overall EGJ contractility
was attributable to the CD.116 Furthermore, analysis of 3D-HRM
recordings differentiating the CD and LES constituents of the
EGJ pressure complex demonstrated that the CD component
correlated strongly with the EGJ-CI, suggesting that both are
largely determined by CD contractility.117 Together, these studies
provide physiological support for adopting the EGJ-CI as a good
summary metric of EGJ barrier function, although with the
caveat that the metric is largely an indicator of CD contractility.

Oesophageal peristaltic function
Oesophageal peristalsis can be characterised by the DCI which
summarises the vigour of post-transition zone contraction
(figure 2).107 A DCI threshold of 450 mm Hg·cm·s correlates
with an averaged distal peristaltic amplitude of 30 mm Hg118,
1355
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Figure 2 High-resolution manometry metrics used in the motor classification of GERD. The oesophagogastric junction contractile integral (EGJ-CI)
measures vigour of the EGJ barrier using a software tool that encompasses length and vigour of the EGJ above the gastric baseline. The measurement
is made over three respiratory cycles during quiet rest, and corrected for duration of respiration. The distal contractile integral (DCI) measures vigour
of smooth muscle contraction taking length, duration and amplitude of contraction into consideration. Following a series of repetitive swallows
(multiple rapid swallows (MRS)), DCI augments higher than mean DCI from single swallows when there is contraction reserve.

Recent advances in clinical practice
Table 2

Classification of motor function in GERD using oesophageal high-resolution manometry
Description

 Morphology

Separation between LES and CD

Type 1: superimposed LES and CD
Type 2: axially separated LES and CD pressure signals separated by
<3 cm
Type 3a: ≥3 cm separation between the LES and CD pressure
signatures with respiratory inversion point at the level of the CD
Type 3b: ≥3 cm separation between the LES and CD pressure
signatures with respiratory inversion point at the level of the LES

 Vigour

EGJ-CI (mm Hg·cm)

DCI box set to encompass the LES and CD over a period of three
complete respiratory cycles above a threshold pressure of the gastric
baseline

Distal contractile integral, DCI (mm Hg·cm·s)
Defect (measure at 20 mm Hg isobaric contour)

Intact: ≥50% of contractions with DCI >450 mm Hg·cm·s and no defect
Fragmented: ≥50% of contractions with DCI >450 mm Hg·cm·s and
defect >5 cm
Ineffective oesophageal motility: ≥50% of contractions with DCI
<450 mm Hg·cm·s
Absent peristalsis: 100% of contractions with DCI <100 mm Hg·cm·s

 MRS (five liquid swallows—2 mL each—taken
<4 s apart)

Contractile response
Failure of contractile response

Post-MRS DCI augmentation
Absent post-MRS contraction

 RDC (free water drinking of 200 mL of water
within 30 s)

Panoesophageal pressurisation
LES relaxation
Effective post-RDC contraction

Oesophageal body motor function

Provocative tests

CD, crural diaphragm; DCI, distal contractile integral; EGJ-CI, o esophagogastric junction contractile integral; LES, lower o esophageal sphincter; MRS, multiple rapid swallows;
RDC, rapid drink challenge.

the original manometric threshold defining ineffective swallows. When abnormal, oesophageal peristalsis is often weak in
GERD,119–121 with poor and/or delayed formation of post-transition zone contraction segment.122 This can result in major
breaks (>5 cm) in the peristaltic contour even when contraction
vigour is preserved, a condition termed fragmented peristalsis
when ≥50% of test swallows demonstrate this finding.107
Peristaltic dysfunction becomes progressively more common
going from NERD to erosive oesophagitis, to Barrett’s oesophagus.123 124 High proportions of ineffective contractions increase
the likelihood of abnormal AET, particularly while supine,125
and increase the likelihood of reflux symptoms.126 The Chicago
Classification defines ineffective oesophageal motility (IEM)
as ≥50% of test swallows with DCI <450 mm Hg·cm·s, inclusive of any combination of weak (DCI 100–450 mm Hg·cm·s) or
failed (DCI <100 mm Hg·cm·s) sequences.107 Failed sequences
are more predictive of an abnormal AET than a similar proportion of weak sequences.127 The greatest reflux burden is seen
with absent contractility (100% of test swallows with DCI
<100 mm Hg·cm·s).128

Provocative tests

The physiological phenomenon of deglutitive inhibition is more
pronounced with multiple swallows in rapid succession such
that the oesophagus remains in inhibition until after the final
swallow, which is then followed by a peristaltic contraction.129
MRS and rapid drink challenge (RDC) are two provocative tests
of the integrity of deglutitive inhibition during HRM.130 With
MRS, five 2 mL swallows are taken <4 s apart and with RDC
200 mL of water is swallowed within 30 s. The Lyon Consensus
proposes that every HRM study should be accompanied by at
least one of these provocative tests.
Post-MRS contractions are an indicator of ‘contraction
reserve’ in the oesophagus, the phenomenon wherein the
post-MRS contraction has greater DCI than the preceding test
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swallows (figure 2).131 Recent data suggest three MRS sequences
for reliable assessment of contraction reserve.132 The absence
of contraction reserve in IEM is predictive of the poor efficacy
of promotility drugs,133 higher AET in NERD,89 outlet obstruction and subsequent benefit from dilation following ARS134 135
and persistence or development of IEM after ARS.136 Absent
contraction reserve is also the most common manometric finding
in systemic sclerosis.137 The Lyon Consensus accepted the value
of adopting MRS into HRM protocols for determining contraction reserve in IEM or absent contractility,107 acknowledging
that MRS is the most widely studied provocative test,131 135 138
provides a computationally simple endpoint (peristaltic augmentation ratio: post-MRS vs pre-MRS)137 and is quick and easy to
perform.
In contrast to MRS, the most important clinical application
of RDC is in distinguishing EGJ obstruction from achalasia, by
identifying LES relaxation in the former, and an exaggerated
pressure gradient across a non-relaxed EGJ in the latter.139–141
Therefore, RDC is most helpful in detecting panoesophageal
pressurisation in achalasia, identifying increased resistance to
EGJ outflow and uncovering latent hypercontractility.139 Additionally, RDC may offer supportive evidence for erosive GERD;
effective post-RDC peristalsis was seen in 83% of healthy
controls compared with 70% of patients with NERD and only
30% of patients with erosive oesophagitis.142 Solid test meals
have also been used as provocative tests during HRM, mainly
in evaluating transit symptoms.142–145 Normal values of oesophageal pressure responses to RDC and solid meals have been
recently reported in normal healthy volunteers.145 146
HRM studies performed during the postprandial period could be
of interest for identification of pathophysiological mechanisms in
GERD,147 148 particularly reflux episodes that tend to be postprandial. A reflux episode may occur during a TLESR, from low LES
pressure, or in conjunction with rumination (increased gastric pressure with or without decreased thoracic pressure) or supragastric
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Table 3

Comparison of the Porto and the Lyon Consensus conclusions
Lyon Consensus

No discussion of endoscopy

Conclusive endoscopic criteria for GERD
►► LA grade C or D oesophagitis;
►► Biopsy-proven Barrett’s oesophagus;
►► Peptic stricture.

Oesophageal impedance monitoring is the only recording method that can
achieve high sensitivity for detection of all types of reflux episodes while pH
monitoring is required for characterisation of reflux acidity. However, the role
of impedance monitoring in the management of patients with GERD still needs
to be defined.

pH-impedance monitoring is the gold standard for detection and characterisation of reflux
episodes but is expensive, not widely available and interpretation is time consuming.
When reflux monitoring is indicated on PPI, pH-impedance should be performed.
When reflux monitoring is indicated off PPI, the choice between catheter-based pH-monitoring,
wireless pH monitoring and pH-impedance monitoring is dependent on cost and availability.

No discussion of the conditions (off or on PPI) to perform reflux testing

Reflux monitoring is recommended off PPI in instances of ‘unproven’ GERD and on PPI in
instances of ‘proven GERD’ (previous LA grade C or D oesophagitis, biopsy-proven Barrett’s
oesophagus, peptic stricture or AET off PPI >6%).

No discussion of normal values

An AET <4% is normal and an AET >6% is abnormal (whatever the type of reflux monitoring and
whether the study was performed off or on PPI).

No discussion of normal values

Reflux episodes >80/24 hours is abnormal and <40 is physiological on pH-impedance performed
off or on PPI. Number of reflux episodes is an adjunctive metric to be used when AET is borderline
or inconclusive.

Basal intraluminal impedance is abnormally low in patients with oesophageal
mucosal abnormalities such as Barrett’s oesophagus or oesophagitis.

Measurement of baseline mucosal impedance (using either through the scope device or MNBI
during ambulatory pH-impedance monitoring) is an adjunctive metric for the diagnosis of GERD.

No discussion of reflux-symptom association

A combination of a positive SI and positive SAP provides the best evidence of clinically relevant
association between reflux episodes and symptoms.

Using manometry, common cavities occur during a higher proportion of reflux Oesophageal high-resolution manometry is not useful for the direct diagnosis of GERD but can
episodes in neonates and infants than in adults.
provide adjunctive information:
No discussion of oesophageal motor function in GERD
►► to assess EGJ barrier function including its morphology (type I to III) and its vigour (using
EGJ-CI);
►► to evaluate oesophageal body motor function (intact, ineffective, fragmented or absent
contractility) that correlates with oesophageal reflux burden;
►► adjunctive tests should be included in the HRM protocol;
►► to evaluate the contractile response (multiple rapid swallow);
►► to evaluate EGJ obstruction (rapid drink challenge test).
Bilitec is a monitoring system that can detect duodeno-gastro-oesophageal
reflux by using the optical properties of bilirubin.

Bilitec is no longer considered a reliable diagnostic tool for GERD and was not discussed.

AET, acid exposure time; EGJ-CI, o sophagogastric junction contractile integral; HRM, high-resolution manometry; PPI, proton pump inhibitors ; SAP, Symptom Association
Probability; SI, Symptom Index.

Table 4

GERD phenotypes predicting abnormal reflux burden from clinical evaluation and oesophageal testing
Pathological GERD
High likelihood

Intermediate likelihood

Low likelihood

Modifiers

 Symptoms

Heartburn, acid regurgitation

Chest pain

Cough, laryngeal symptoms

Hypersensitivity and hypervigilance

 Endoscopy

High-grade oesophagitis, Barrett’s
mucosa, peptic stricture

Low-grade oesophagitis, normal
exam on PPI therapy

 ROME IV

NERD (abnormal pH-metry)*

Symptom response to PPI therapy

Reflux hypersensitivity functional
heartburn, functional chest pain

Hypersensitivity and hypervigilance

 Lyon Consensus*

Conclusive evidence of GERD

Borderline or inconclusive evidence

Physiological reflux parameters

Novel metrics
Motor classification

 Pattern of reflux

Increased acid exposure
±increased numbers of reflux
episodes*

Borderline acid
exposure±borderline numbers of
reflux episodes*

Normal reflux metrics

pH of refluxate, baseline
impedance, hypochlorhydria,
achlorhydria

 Mechanism of reflux

TLESR
Hypotensive EGJ
Abnormal EGJ morphology

Supragastric belch
Rumination

Normal EGJ morphology and
function

Obesity, increased abdominal girth

 Clearance of refluxate

Absent contractility
Hiatus hernia

Minor motor disorder±contraction
reserve

Normal peristalsis

Xerostomia, baseline impedance,
PSPW index, motor classification

Increased perception

Visceral hypersensitivity,
hypervigilance

Anxiety, depression
Panic disorder

Clinical phenotypes
Hiatus hernia, ongoing PPI therapy

Mechanistic phenotypes

 Cognition, perception of Appropriate symptom perception,
sensation
symptom reflux association

*As described by the Lyon Consensus, figure 3.
EGD, oesophagogastroduodenoscopy; EGJ, oesophagogastric junction; NERD, non-erosive reflux disease; PSPW, postreflux swallow-induced peristaltic wave; TLESR, transient
lower oesophageal sphincter relaxation.
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belching (air swallowing to initiate belching).147 Postprandial HRM
has also been used to evaluate the efficacy of drugs targeted to
TLESRs, rumination and supragastric belching.149 150 However,
several limitations exist, including lack of normative postprandial
HRM data, difficulties with standardisation of the test meal and
unclear optimal duration of the recording period.

Classification of motility findings in GERD

The most common motility pattern in GERD is a normal study.
However, either the EGJ or the oesophageal body, or both can be
abnormal. The EGJ can be hypotensive, with or without a hiatus
hernia. Peristalsis can be fragmented, ineffective or absent, with
or without contraction reserve. The Lyon Consensus endorses the
hierarchical classification of motility findings in GERD first evaluating EGJ morphology and function with LES-CD separation
and the EGJ-CI, second characterising the integrity of peristalsis
as normal, weak, fragmented or absent and third, evaluating for
contraction reserve7 (table 2). This classification is intended to
be used in conjunction with the Chicago Classification.

Advances since the Porto Consensus

The Lyon Consensus builds on the Porto Consensus of 2002,45
providing recommendations for the use and interpretation of reflux
testing techniques in 2018 including oesophageal HRM and baseline impedance measurement that were not widely available in 2002
(table 3). The primary indication for reflux testing is in distinguishing
among patients with pathological reflux burden, reflux-mediated
hypersensitivity and functional syndromes (table 4).151 The Lyon
Consensus attempts to augment this approach by stratifying the
significance of findings into those that are conclusive of pathological GERD, as opposed to suggestive of the diagnosis (figure 3). The
Lyon Consensus also proposes the concept of ‘borderline’ or inconclusive evidence when additional evidence can sway the final judgement towards or away from GERD. This is an area where novel
metrics and diagnostic techniques may prove helpful. Conditions
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that can mimic GERD, such as achalasia, supragastric belching and
rumination syndrome need to be excluded with appropriate testing.

Optimisation of GERD testing

GERD symptoms are diverse, response to treatment is variable,
pathogenesis is heterogeneous and mechanistic phenotypes are
heavily influenced by hypersensitivity and hypervigilance. Because
simple algorithms starting with a PPI trial do not consider these
complex phenotypes of GERD, they often lead to inappropriate PPI
utilisation, delayed diagnosis and inaccurate diagnoses.152 The Lyon
Consensus opines that the optimal initial testing for PPI non-responders with no prior endoscopic or pH-metry demonstration
of GERD is pH or pH-impedance monitoring done withholding
antisecretory therapy. A key potential outcome of that testing is to
rule out GERD and to redirect management towards weaning off
PPIs, using neuromodulators and/or cognitive behavioural therapy
as appropriate. In contrast, optimal testing in poorly responsive
patients with a prior demonstration of GERD is the combination
of EGD, HRM and pH-impedance monitoring done on twice-daily
PPI therapy. This combination of tests serves both to redirect therapy
towards alternative diagnoses and to mechanistically subtype
patients in terms of poor clearance, excessive reflux episodes and
hypersensitivity (table 4), each of which can trigger specific management options. The precise roles of baseline impedance, PSPW index
and provocative manoeuvres on HRM remain to be clarified with
future research.

Outcome measures in GERD

The optimal use of diagnostic testing may translate into better therapeutic outcomes, but appropriate outcome measures are necessary to properly evaluate that improvement. Oesophagitis healing
is a common measure for therapeutic trials, but visible oesophagitis is rare in patients with refractory GERD symptoms,24 and
the objective of the evaluation is to determine if refractory symptoms are attributable to GERD or not. Hence, potentially relevant
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Figure 3 Interpretation of oesophageal test results in the context of GERD. Any one conclusive finding provides strong evidence for the presence
of GERD. While a normal EGD does not exclude GERD on its own, this provides strong evidence against GERD when combined with AET <4% and
<40 reflux episodes on pH-impedance monitoring off proton pump inhibitor therapy. When evidence is inconclusive or borderline, adjunctive or
supportive findings can add confidence to the presence or absence of GERD. Histopathology as an adjunctive measure requires a dedicated scoring
system (incorporating papillary elongation, basal cell hyperplasia, DIS, intraepithelial inflammatory cells, necrosis and erosions) or evidence of DIS
on electron microscopy. However, adjunctive findings, particularly histopathology and motor findings in isolation, are not enough to diagnose GERD.
AET, acid exposure time; DIS, dilated intercellular spaces; MNBI, mean nocturnal baseline impedance; HRM, high-resolution manometry; PSPWI index,
postreflux swallow-induced peristaltic wave index; EGJ, oesophagogastric junction. *Factors that increase confidence for presence of pathological
reflux when evidence is otherwise borderline or inconclusive.

Recent advances in clinical practice

Conclusions and future direction
GERD is a complex disease with a heterogeneous symptom
profile and a multifaceted pathogenic basis that defies a simple
diagnostic algorithm or categorical classification. The Lyon
Consensus defines parameters on oesophageal testing that
conclusively establish the presence of GERD and characteristics
that rule out GERD. Additional evidence from reflux-symptom
association, motor findings on HRM, novel metrics from
pH-impedance monitoring, baseline mucosal impedance and
PPI response complement oesophageal testing when pH-metry is
borderline or inconclusive. While acknowledging the limitations
of currently available oesophageal testing in GERD, the Lyon
Consensus proposes this model as a guide to direct management.
The future approach to phenotyping patients with GERD
should focus on assessing important physiological biomarkers
and PROs to categorise patients based on the severity of
refluxate exposure, mechanism of reflux, effectors of clearance
and underlying EGJ pathophysiology (table 4), while recognising
that no single approach is perfect. Novel metrics assessing tissue
resistance, oesophageal clearance, peripheral and central neural
integration and psychometrics will allow for a tailored therapeutic approach including pharmacological treatments, surgical/
endoscopic interventions and behavioural strategies targeting
the underlying defect(s) in the antireflux barrier, oesophageal
clearance, visceral sensitivity and cognitive response to reflux. As
newer metrics emerge, the Lyon Consensus plans future meetings to update and adapt the consensus conclusions. Collaboration between high volume medical centres involved in GERD
testing has opened possibilities for more robust normative data
and for validation of conclusions and recommendations from
the Lyon Consensus. As the GERD diagnostic paradigm evolves,
using diagnostic testing to define a precision approach tailored
to the individual patient becomes possible. The goals of evaluation should therefore transition towards defining GERD phenotypes to facilitate tailored treatment.
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